Rapidly evaluate the cytotoxicity profile of your therapeutic candidates in high throughput
Leveraging Horizon Discovery’s extensive expertise in high throughput screening, we provide analysis and interpretation of the cytotoxic effects of your candidates in our highly reproducible Complement-Dependent Cytotoxicity (CDC) assays and NK cell Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) assays.
The diagram below shows an outline of the steps involved in our ADCC/CDC assay service, with your own therapeutic added alone or in combination, through to assessment of tumor cells by released calcein.
Figure 1. ADCC assays. Anti-CD20 antibody rituximab dose-dependently induces cytotoxicity of NK cells against CD20+ Daudi cells as measured by calcein release.
Figure 2. CDC assays. Rituximab dose-dependently induces cytotoxicity against Daudi cells in the presence of human serum as measured by calcein release.
To find out more about how Horizon's ADCC and CDC assay services could help with your immune-oncology research, get in contact with our team today.